Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study

Table 2

Clinical characteristics of patients with ulcerative colitis (UC) treated with tacrolimus (TAC) group who were randomly assigned to maintenance therapy with TAC, AZA, or TAC + AZA.

	TAC ()	AZA ()	TAC + AZA ()	value
Male/female	9/4	7/6	6/8	NS
Age (years)	49.7 ± 16.4	42.4 ± 14.3	39.4 ± 15.3	NS
Duration of UC (years)	7.3 ± 7.7	11.3 ± 10	7.7 ± 8.2	NS
Follow-up time (days)	693 ± 359	1205 ± 349	806 ± 362	<0.05
Pancolitis/left-sided colitis	9/4	7/6	8/6	NS
Past AZA therapy (yes/no)	9/4	9/4	8/6	NS
Baseline CAI	13.7 ± 3.7	13.6 ± 3.0	13.5 ± 2.5	NS
Time to reach target blood TAC level (days)	3.6 ± 2.6	5.0 ± 2.5	3.9 ± 2.5	NS
TAC treatment time (days)	402 ± 167	87 ± 12	240 ± 166	—
Baseline Hb (g/dL)	10.8 ± 24	12.1 ± 2.3	13.3 ± 2.1	NS
Baseline CRP (mg/dL)	2.2 ± 2.7	3.7 ± 5.2	1.1 ± 0.7	NS
Mayo	3.0 ± 0.0	3.0 ± 0.0	3.0 ± 0.0	NS
UCEIS	6.3 ± 1.1	6.6 ± 1.8	6.4 ± 1.1	NS
EAI	13.5 ± 2.1	13.9 ± 1.6	13.6 ± 1.5	NS